Back to Search
Start Over
Autologous peripheral blood mononuclear cell recognition of autologous proliferating tumor cells in the context of a patient-specific vaccine trial
- Source :
- Journal of Biomedicine and Biotechnology. January 1, 2011
- Publication Year :
- 2011
-
Abstract
- Metastatic melanoma patients who were treated with patient-specific vaccines consisting of dendritic cells loaded with autologous tumor cells had a 5-year survival of over 50%. Enzyme-linked immunospot (ELISPOT) has been used to detect antigen reactive T cells as a means of determining immune response. We wished to determine whether IFN-gamma secretion in an ELISPOT assay was prognostic or predictive for survival following treatment. Peripheral blood mononuclear cells (PBMCs) collected at weeks 0 and 4 were evaluated by ELISPOT assay for response to autologous tumor cells. Overall, there was slight increase in the number of tumor reactive lymphocytes from week 0 to week 4. Using >5 spots/100 K PBMC as the cutoff, a log-rank analysis revealed only a slight statistical significance in overall survival for patients who lacked tumor reactive PBMCs at week 4. The sensitivity of ELISPOT in the context of patient-specific cellular vaccines is unclear.<br />1. Introduction Metastatic melanoma is generally considered to be incurable. Immunotherapy is a promising alternative treatment to chemotherapy, but challenges remain in determining response to therapy. Clinical trials that use [...]
Details
- Language :
- English
- ISSN :
- 11107243
- Database :
- Gale General OneFile
- Journal :
- Journal of Biomedicine and Biotechnology
- Publication Type :
- Academic Journal
- Accession number :
- edsgcl.266629868
- Full Text :
- https://doi.org/10.1155/2011/635850